PHILADELPHIA, July 7, 2026 — Dr. Carl June, director of the Center for Cellular Immunotherapies at the University of Pennsylvania, is widely recognized as a pioneer of CAR-T therapy. His team published the first successful clinical trial in 2011, treating three patients with chronic lymphocytic leukemia. Among them was Emily Whitehead, who became the first child to receive CAR-T therapy in 2012 and remains cancer-free as of 2024.
That 2011 trial marked a turning point. For communities across Asia, where access to advanced cancer treatments has long been uneven, the progress since then offers a measure of hope. CAR-T therapy, which reprograms a patient’s own immune cells to attack cancer, has moved from a laboratory concept to a regulated treatment available in multiple countries.
From one patient to a wave of approvals
Novartis, which licensed the University of Pennsylvania’s technology, received the first U.S. Food and Drug Administration approval for Kymriah in 2017. That same year, Kite Pharma, a Gilead Sciences subsidiary, developed Yescarta, approved for large B-cell lymphoma. Bristol-Myers Squibb markets Breyanzi, approved in 2021 for certain lymphomas and in 2024 for chronic lymphocytic leukemia and small lymphocytic lymphoma.
For families across the region, the expansion of approved indications means more patients may eventually become eligible for these therapies. Johnson & Johnson and Legend Biotech developed Carvykti (ciltacabtagene autoleucel), approved in 2022 for multiple myeloma. Legend Biotech, a company with roots in China and operations in the United States, represents one of the most direct links between Asian biotechnology and the global CAR-T market.
What comes next: next-generation therapies
As of 2024, over 30 companies are developing next-generation CAR-T therapies. That includes CRISPR-edited allogeneic, or off-the-shelf, versions from companies like CRISPR Therapeutics and Allogene Therapeutics. These approaches aim to solve one of the biggest barriers to wider use: the cost and complexity of manufacturing a personalized treatment for each patient.
Closer to home, the implications are significant. Many healthcare systems in Asia face high demand for cancer care and limited budgets. Off-the-shelf CAR-T products, if successful, could reduce manufacturing time and potentially lower costs. That would bring the therapy within reach of more patients, not just those in wealthy urban centers.
Dr. June’s work continues to shape the field. The University of Pennsylvania remains a hub for cellular immunotherapy research, and the pipeline of clinical trials shows no sign of slowing. For communities across Asia, the question is not whether CAR-T therapy will arrive, but how quickly it can be adapted to local needs and regulatory frameworks.
Consult your doctor for medical advice.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Academic Pioneers to Pharma Giants Drive CAR-T Therapy”, “description”: “PHILADELPHIA, July 7, 2026 — Dr. Carl June, director of the Center for Cellular Immunotherapies at the University of Pennsylvania, is widely recognized as a…”, “datePublished”: “2026-07-07T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Merry Gel Sigui”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
